A Phase 3 Randomized Placebo-Controlled Double-Blind Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type Advanced or Recurrent Endometrial Carcinoma (GOG 3083)
Brief description of study
The purpose of this research study is to further evaluate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer.
Clinical Study Identifier: s22-01114
ClinicalTrials.gov Identifier: NCT05611931
Principal Investigator:
Bhavana Pothuri.
Other Investigators:
Jaime Lynn Moyles,
Marina Stasenko,
Michelle Diane Swanson Lightfoot,
Emeline Mariam Aviki,
Kent Chan,
Edward A Jimenez,
Erin Annette Reese,
Fabia Brisard Pierrot,
Caitlin Elizabeth Ryan,
Whitfield B. Growdon,
Christina Grace Wilson,
Deanna Gerber,
Eva Chalas-Westermann,
Alexander A Hindenburg,
Jagdeep Raince,
Kelly A Levine,
Olivia Richardson Khouri,
Kathleen M Lutz,
Leslie R Boyd.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.